Cargando…

Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis

BACKGROUND: This study evaluates the effects of active (1α-hydroxylated) vitamin D (AVD) therapy on hypercalcaemia in patients with non-dialysis chronic kidney disease (ND-CKD) and secondary hyperparathyroidism (SHPT). METHODS: A systematic search of the PubMed, Embase and Cochrane Library databases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cozzolino, Mario, Bernard, Laurence, Csomor, Philipp A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573010/ https://www.ncbi.nlm.nih.gov/pubmed/34754440 http://dx.doi.org/10.1093/ckj/sfab091

Ejemplares similares

Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease
por: Strugnell, Stephen A., et al.
Publicado: (2023)

Hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary?
por: Lunn, Mitchell R., et al.
Publicado: (2010)

Hypercalcaemia with Hypocalcuria, an Unusual Case of Primary Hyperparathyroidism
por: Forbes, H. A. W., et al.
Publicado: (1956)

Primary hyperparathyroidism presenting as acute psychosis secondary to hypercalcaemia requiring curative parathyroidectomy
por: Singh, Prateush, et al.
Publicado: (2018)

Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis
por: Bover, Jordi, et al.
Publicado: (2021)

Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide
por: Dachy, Guillaume, et al.
Publicado: (2021)

Vitamin D toxicity and hypercalcaemia
por: Singh, Pooja, et al.
Publicado: (2021)

The Neurological Aspects of Hypercalcaemia: With Special Reference to Primary Hyperparathyroidism
por: Henson, R. A.
Publicado: (1966)

Hypercalcaemia and Primary Hyperparathyroidism – an Underappreciated Contributor to Psychiatric Presentations
por: Ghoneim, Fatma, et al.
Publicado: (2023)

Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022)

Management of severe hypercalcaemia secondary to primary hyperparathyroidism: The efficacy of saline hydration, furosemide, and zoledronic acid
por: Oueslati, Ibtissem, et al.
Publicado: (2022)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

ODP099 Hyperparathyroidism Causing life Threatening Hypercalcaemia in Pregnancy
por: Lee, Jessica, et al.
Publicado: (2022)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
por: Friedl, Claudia, et al.
Publicado: (2017)

Infantile hypercalcaemia type 1: a vitamin D-mediated, under-recognised cause of hypercalcaemia
por: Nizar, Ryizan, et al.
Publicado: (2021)

Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D
por: Cozzolino, Mario, et al.
Publicado: (2021)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Vitamin D toxicity presenting with altered sensorium and hypercalcaemia
por: Sarma, Anuj
Publicado: (2020)

Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease
por: Sonkar, Satyendra Kumar, et al.
Publicado: (2018)

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study
por: Roggeri, Daniela Paola, et al.
Publicado: (2014)

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
por: Germain, Michael J., et al.
Publicado: (2022)

Increased rates of infantile hypercalcaemia following guidelines for antenatal vitamin D3 supplementation
por: Amato, Lisa A, et al.
Publicado: (2015)

Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future
por: Brandenburg, Vincent, et al.
Publicado: (2022)

A novel CASR variant in a family with familial hypocalciuric hypercalcaemia and primary hyperparathyroidism
por: Sagi, Satyanarayana V, et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Exacerbation of Hyperparathyroidism, Secondary to a Reduction in Kidney Function, in Individuals With Vitamin D Deficiency
por: Daimon, Makoto, et al.
Publicado: (2020)

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
por: Franchi, Matteo, et al.
Publicado: (2023)

Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Vitamin D intoxication and severe hypercalcaemia complicating nutritional supplements misuse
por: Alkundi, Alamin, et al.
Publicado: (2022)

Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
por: Davies, Evan W., et al.
Publicado: (2015)

Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease
por: Ketteler, Markus, et al.
Publicado: (2021)

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency
por: Elbers, Laura P B, et al.
Publicado: (2018)

Opioid-induced secondary adrenal insufficiency presenting as hypercalcaemia
por: Lee, Angela S, et al.
Publicado: (2015)

“The cat and the calcium”. A case of delirium secondary to hypercalcaemia.
por: Jiménez Aparicio, T., et al.
Publicado: (2023)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Vitamin D in Chronic Kidney Disease and Dialysis Patients
por: Jean, Guillaume, et al.
Publicado: (2017)

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
por: Xie, Yifeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n20s7h6pse5l4jli8uf1or9mqu